Neonc Technologies Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NTHI research report →
Range $13 – $20
Price Chart
About the company
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases.
- CEO
- Amir Farrokh Heshmatpour
- IPO
- 2025
- Employees
- 5
- HQ
- Calabasas, CA, US
Get TickerSpark's AI analysis on NTHI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $90.88M
- P/E
- -1.70
- Fwd P/E
- 4.12
- PEG
- 0.55
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -2.35
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 349.31%
- ROIC
- 316.10%
Latest fiscal year · YoY change
- Revenue
- $39.99K+0.0%
- Gross Profit
- $39.99K+0.0%
- Op Income
- $-58,169,198
- Net Income
- $-62,146,210+0.0%
- EPS
- $-3.23+0.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $11.38
- 52W Low
- $2.50
- 50D MA
- $3.29
- 200D MA
- $5.08
- Beta
- 0.50
- RSI (14)
- 42
- Avg Volume
- 187.23K
No earnings-call transcripts are available for NTHI yet.
- Free Float
- 22.1%
- Shares Outstanding
- 28.85M
- Float Shares
- 6.36M
of shares held by institutions
22 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Cinctive Capital Management LP | 1.61M | ▲ 181.94K |
| Vanguard Capital Management LLC | 393.51K | ▼ 110.67K |
| Bank Of America Corp | 224.41K | ▼ 10.98K |
| Westmount Partners, LLC | 197.18K | 0 |
| Vanguard Group Inc | 181.03K | ▲ 40.12K |
| Blackrock, Inc. | 178.22K | ▼ 1.63K |
| Geode Capital Management, LLC | 161.04K | ▼ 5.08K |
| Marshall Wace, Llp | 114.05K | ▲ 92.26K |
| Vanguard Fiduciary Trust Co | 64.34K | ▼ 27.14K |
| Morgan Stanley | 57.75K | ▲ 42.10K |
| State Street Corp | 43.17K | 0 |
| Northern Trust Corp | 35.87K | ▲ 12.60K |
Held by 24 ETFs
Biggest fund positions in NTHI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 13, 26 | Heshmatpour Amir F | buy | 30,000 |
| Nov 10, 26 | CHEN THOMAS C | buy | 2,284 |
| Nov 9, 26 | CHEN THOMAS C | buy | 2,732 |
| Nov 11, 26 | Heshmatpour Amir F | buy | 10,000 |
| Nov 11, 26 | Heshmatpour Amir F | buy | 10,000 |
| Nov 10, 26 | Heshmatpour Amir F | buy | 50,000 |
| Nov 9, 26 | Heshmatpour Amir F | buy | 10,000 |
| Nov 6, 26 | Heshmatpour Amir F | buy | 40,000 |
| Nov 5, 26 | Heshmatpour Amir F | buy | 30,000 |
| Oct 9, 26 | ALABEDIN ALI MOHAMMAD AHMAD MOHAMMAD | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NTHI coverage
Recent articles, reports, and earnings notes.
No research on NTHI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NTHI report →NeOnc Technologies Announces FDA Rescheduled NEO212 End-of-Phase 1 Type B Meeting to November 23
globenewswire.com · Nov 19
NeOnc Reports Additional Partial Response in Phase 2a Study of Intranasal NEO100
globenewswire.com · Nov 17
NeOnc CEO Amir Heshmatpour's 2026 Open-Market Share Purchases Exceed $1.5 Million
globenewswire.com · Nov 16
NeOnc Showcases Two Brain Cancer Drug Programs at SNO as FDA Meetings Approach
globenewswire.com · Nov 13
NeOnc CEO Buys More Shares Below $5 as NTHI Secures FDA Meeting to Discuss Phase 3 Trial
globenewswire.com · Nov 12
NeOnc Insider Buying Expands Ahead of FDA Discussions and Two Key Brain Cancer Data Presentations
globenewswire.com · Nov 12
FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track
globenewswire.com · Nov 11
NeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100
globenewswire.com · Nov 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.